Nag DS, Swain A, Sahu S, Sen B, Vatsala, Parween S. Stroke: Evolution of newer treatment modalities for acute ischemic stroke. World J Clin Cases 2024; 12(28): 6137-6147 [PMID: 39371560 DOI: 10.12998/wjcc.v12.i28.6137]
Corresponding Author of This Article
Deb Sanjay Nag, MD, Doctor, Department of Anaesthesiology, Tata Main Hospital, C Road West, Northern Town, Jamshedpur 831001, India.ds.nag@tatasteel.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 6, 2024; 12(28): 6137-6147 Published online Oct 6, 2024. doi: 10.12998/wjcc.v12.i28.6137
Stroke: Evolution of newer treatment modalities for acute ischemic stroke
Deb Sanjay Nag, Amlan Swain, Seelora Sahu, Biswajit Sen, Vatsala, Sadiya Parween
Deb Sanjay Nag, Amlan Swain, Seelora Sahu, Biswajit Sen, Vatsala, Sadiya Parween, Department of Anaesthesiology, Tata Main Hospital, Jamshedpur 831001, India
Amlan Swain, Seelora Sahu, Department of Anaesthesiology, Manipal Tata Medical College, Jamshedpur 831017, India
Author contributions: Nag DS and Swain A designed the overall concept and outline of the manuscript; Sahu S, Sen B, Vatsala, and Parveen S were contributed to the discussion and design of the manuscript; all authors were contributed to the writing, and editing of manuscript and review of literature.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deb Sanjay Nag, MD, Doctor, Department of Anaesthesiology, Tata Main Hospital, C Road West, Northern Town, Jamshedpur 831001, India.ds.nag@tatasteel.com
Received: March 8, 2024 Revised: June 8, 2024 Accepted: July 3, 2024 Published online: October 6, 2024 Processing time: 158 Days and 1.6 Hours
Abstract
Acute ischemic stroke is one of the leading causes of morbidity and mortality worldwide. Restoration of cerebral blood flow to affected ischemic areas has been the cornerstone of therapy for patients for eligible patients as early diagnosis and treatment have shown improved outcomes. However, there has been a paradigm shift in the management approach over the last decade, and with the emphasis currently directed toward including newer modalities such as neuroprotection, stem cell treatment, magnetic stimulation, anti-apoptotic drugs, delayed recanalization, and utilization of artificial intelligence for early diagnosis and suggesting algorithm-based management protocols.
Core Tip: Acute ischemic stroke is becoming a more prevalent health concern as life expectancies increase. The fact that thrombolysis and thrombectomy within a very limited timeframe are the only definite therapies for this debilitating disease severely limits options. Extensive research is still ongoing and has shown promise in salvaging neurological function as well as extending the time window in which such therapies can be offered to stroke patients.
